AbbVie Acquires Syndesi Therapeutics
March 1, 2022
AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.
- Buyers
- AbbVie
- Targets
- Syndesi Therapeutics
- Sellers
- Novo Holdings, UCB Pharma, V-Bio Ventures, Vives Fund, Syndicate of Belgian and international investors
- Industry
- Biotechnology
- Location
- Belgium
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion
April 6, 2026
Healthcare Services
Neurocrine Biosciences entered into a definitive agreement to acquire Soleno Therapeutics in an all-cash transaction valued at approximately $2.9 billion. The deal adds Soleno’s first-in-class therapy VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome to Neurocrine’s commercial portfolio, and is expected to close within 90 days subject to customary conditions and regulatory approvals.
-
Sanofi to Acquire Vicebio for Up to $1.6 Billion
July 25, 2025
Healthcare Services
Sanofi has entered an exclusive, definitive agreement to acquire biopharmaceutical company Vicebio for up to US$1.6 billion, comprising a US$1.15 billion upfront payment plus up to US$450 million in development and regulatory milestones. The deal is aimed at accelerating Vicebio’s next-generation respiratory virus vaccine platform, including lead candidate VXB-241 targeting RSV and hMPV.
-
AbbVie Acquires Nimble Therapeutics in $200 Million Deal
January 23, 2025
Biotechnology
AbbVie announced and later completed the acquisition of Nimble Therapeutics for $200 million in cash at closing, plus interim funding and potential development milestone payments to Nimble shareholders. The deal adds Nimble’s preclinical oral peptide IL23R inhibitor for psoriasis/IBD and its proprietary peptide synthesis, screening, and optimization platform to strengthen AbbVie’s immunology pipeline and R&D capabilities.
-
AbbVie Completes $1.4B Acquisition of Aliada Therapeutics
December 11, 2024
Biotechnology
AbbVie completed its $1.4 billion cash acquisition of RA Capital Management portfolio company Aliada Therapeutics. The deal adds ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in Phase 1 for Alzheimer’s disease, and Aliada’s blood-brain barrier (BBB)-crossing MODEL delivery platform to AbbVie’s neuroscience pipeline.
-
AbbVie Acquires Cerevel Therapeutics
December 6, 2023
Pharmaceuticals
AbbVie (AbbVie Inc.) announced it will acquire Cerevel Therapeutics in a definitive agreement, strengthening its neuroscience pipeline with multiple clinical- and preclinical-stage programs. The deal values Cerevel at about $8.7 billion and is structured as an all-cash purchase of all outstanding Cerevel shares for $45.00 per share.
-
Merck & Co., Inc. Acquires VelosBio Inc.
November 5, 2020
Biotechnology
Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.